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Not All Readmissions
Are Created Equal*
Joseph G. Cacchione, MD
Cleveland, Ohio
In a retrospective review by Hannan et al. (1) in this issue of
JACC: Cardiovascular Interventions, 30-day readmission rates for
percutaneous coronary intervention (PCI) patients were
analyzed using both clinical and administrative datasets to
determine overall readmission rates, planned or staged readmis-
sions, and a determination of predictors for unstaged read-
missions. The 30-day readmission rates categorized using
administrative data in this study underscore the diverse
sources of readmission data and the challenges involved in
their evaluation. Readmissions are an important area of
interest as they are a major cost item and, because they are
considered a failure of the initial care, are often used as a
surrogate of quality (2). Healthcare reform proposals from
the federal government include payment withholdings for
high readmission rates. The Center for Medicare Services’
proposed Hospital Value-Based Purchasing Program in-
cludes penalties on the Inpatient Prospective Payment
System for high rates of preventable readmissions.
See page 1335
In the current study, although the use of the SPARCS
(Statewide Planning and Research Cooperative System) and
PCIRS (Percutaneous Coronary Interventions Reporting
System) databases provide a robust volume of data, it is the
clinical data from the New York State PCIRS that gives us
a unique view of the demographic, clinical, and procedural
predictors of readmission not previously reported for this
population. These results will likely be useful in raising the
awareness of providers to create systems for prevention.
Lastly, readmission data from SPARCS, a claims dataset,
produced a list of diagnoses for readmission that gives some
indication of the reason but cannot identify whether these
were preventable or inevitable.
*Editorials published in JACC: Cardiovascular Interventions reflect the views of the
authors and do not necessarily represent the views of JACC: Cardiovascular Interven-
tions or the American College of Cardiology.
From the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland,
Ohio. Dr. Cacchione has reported that he is on the advisory boards of Humana and
Paragon; and is a consultant for Riner Group. Stephen Ellis, MD, served as GuestrEditor for this paper.Studies of hospital readmissions have generally used
subjective reviews or claims data to answer the question of
avoidable versus unavoidable readmissions (3). Studies using
laims data are limited and subject to variability in the
ischarge diagnostic codes used for reimbursement. The
laims profile for readmissions in the current study for
ardiac-related conditions ranged from chronic ischemic
eart disease in 22.9% of patients to acute myocardial
nfarction in 2.9%. The details of these admissions, the
vents that generated the discharge diagnoses codes, and
hether readmission was avoidable is unclear without in-
ormation that is more precise. Even in circumstances of
linical reviews, the subjective judgment of “avoidable” is
ften difficult and, thus, by their nature, these determina-
ions are less than an exact science. In a study by Van
alraven et al. (4) using subjective reviews, 16% of 180-day
rgent readmissions were deemed potentially avoidable.
he factors contributing to readmission risk included man-
gement error, surgical complications, medication-related
vents, nosocomial infections, system failures, diagnostic
rrors, and a procedural event. These generic categories may
e more directional to establish solutions than the claims
ata used in this analysis, but they are so ambiguous as to
imit their use in driving performance improvement. The
ery nature of reviews based on either method makes
ssessments of potentially avoidable readmissions problem-
tic as markers for quality ratings. If the data used are of
ufficient quality and rigor for identification of patients at
isk of readmission, then quality improvement systems of
are can be designed for prevention and could then poten-
ially be used as a surrogate marker for quality.
Although this retrospective review was not designed to
etermine the degree to which readmissions could have
een avoided, it does yield important insights into the
rivers of readmissions after PCI and the relative rates of
taged versus unstaged readmissions. The former was a
nique aspect to this study that has linkages to the national
ssues of appropriateness and national health expenditures.
taged readmissions, whether appropriate or not, currently
ave a negative connotation as being contrived or unneces-
ary. In the current study, the use of clinical data provides
nsight into the staged events for a second revascularization
rocedure that represented 63.8% of all repeat PCIs within
0 days. In the fee-for-service environment, the implication
f the staged PCI is that it could have been done during the
ndex admission in many cases. Current guidelines would
uggest that staging is appropriate if the first PCI was done
uring an acute myocardial infarction event (5); there are
ther clinical circumstances that would also suggest a staged
vent, as well such as excessive contrast load or radiation
xposure during the first procedure. As payment reform
laces providers at greater financial risk, the issues sur-
ounding “staged” procedures may be less important. A
ecent RAND analysis (6) has shown that provider financial
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1344risk is an approach that successfully bends the financial cost
curve of national health expenditures. The perverse financial
incentive for providers to impart more care has been a
subject for many aspects of healthcare reform discussions.
As highlighted here, the determination of staged events and
their clinical appropriateness is difficult based on claims
data; however, a fixed longitudinal or capitated financial
agreement may mitigate the negative connotation of staging
by removing this incentive. Appropriateness of coronary
revascularization has been under intense scrutiny with very
high-profile cases in the national media (7). The American
College of Cardiology Appropriateness criteria do not defini-
ively address staging, but they do explicitly encourage the
se of these criteria for the development of national pay-
ent strategies to ensure that patients receive care that is
ecessary, beneficial, and cost-effective rather than care
rovided for other reasons (8). In the future, a second PCI
rocedure performed during a separate admission may be
art of a global payment and not reimbursed as a second
vent if there is no clinical reason for the delay. These
elays, as pointed out by the investigators, could postpone
he second procedure to a time beyond a defined readmis-
ion assessment period and, thus, have the potential for
dverse patient outcomes. Also, one could construe this
elay as “gaming” the system beyond the global payment
eriod for better reimbursement.
An additional requirement for providers will include
ggregation of longitudinal data to help determine the
ppropriate use of readmissions or staging as a strategy for
mproved outcomes. The relationship between longitudinal
utcomes and cost will help determine the value of read-
ission and better answer the question of whether readmis-
ion is “good” or “bad.” In addition, the procedural variables that
ere shown to be predictive of readmission here will potentially
uide better strategies for prevention as well as optimize care for
he continuum of patients undergoing PCI. Strategies for opti-
izing length of stay in those PCI patients with higher rates of
eadmission may also assist in better establishing a fair reimburse-
ent for sicker patients. The current reimbursement system
rbitrarily determines admission versus outpatient status for PCI
nd tries to address that issue, but the system is variable and
nevenly enforced. Some clinical criteria have been established to
ry to help frame this arbitrary distinction (9); however, it remains
subject of intense scrutiny by the government and commercial
nsurers.
This study is an important addition to the evolving body
f knowledge regarding readmissions and their etiology.
he causes, measurements, and implications for readmis-
ion in this study and from others are quite diverse. The
etermination whether “avoidable” readmissions are a fail-
re of care, a complication, or are appropriate is a matter
hat requires further study. The current system, which uses
eadmission rates as a surrogate for quality, will continue toe challenged due to the absence of rigorous objective data
o measure avoidability. The reimbursement system may
lay a role in changing the paradigm in which additional
are serves as a financial incentive for providers. Readmis-
ions are not necessarily evil. They are recognized to be
xpensive but are often warranted. The healthcare system
as yet to determine whether long-term costs or outcomes
re improved with an early readmission despite greater
hort-term costs. The implication that readmissions always
epresent a clinical failure or an attempt at ill-gotten gain
ust be tempered. Studies, such as this retrospective review
hould provide the foundation for prospective predictable
odels of readmission to promote better clinical care in a
ore cost-effective environment.
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